ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

Compare

2,414 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACAD Analyst Ratings

Moderate Buy

13 Buy

5 Hold

0 Sell

Based on 18 analysts giving stock ratings to

ACADIA

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACAD Stock 12 Month Forecast

Average Price Target

$30.35

▲(34.47% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $30.35 with a high forecast of $39.00 and a low forecast of $21.00. The average price target represents a 34.47% change from the last price of $22.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","40":"$40","19.75":"$19.75","26.5":"$26.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,19.75,26.5,33.25,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.7,23.953846153846154,25.207692307692305,26.46153846153846,27.715384615384615,28.96923076923077,30.223076923076924,31.476923076923075,32.730769230769226,33.98461538461538,35.238461538461536,36.49230769230769,37.746153846153845,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.7,23.288461538461537,23.876923076923077,24.465384615384615,25.053846153846152,25.642307692307693,26.23076923076923,26.81923076923077,27.407692307692308,27.996153846153845,28.584615384615386,29.173076923076923,29.761538461538464,{"y":30.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.7,22.569230769230767,22.43846153846154,22.307692307692307,22.176923076923078,22.046153846153846,21.915384615384614,21.784615384615385,21.653846153846153,21.52307692307692,21.392307692307693,21.26153846153846,21.130769230769232,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.61,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$39.00

Average Price Target$30.35

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

$28→$29

Buy

28.49%

Upside

Reiterated

11/06/25

Positive Indicators and Growth Prospects Lead to Buy Rating for ACADIA Pharmaceuticals

Ananda Ghosh

H.C. Wainwright

$32

Buy

41.78%

Upside

Reiterated

11/06/25

ACADIA Pharmaceuticals: Strong Growth Prospects and Strategic Positioning Justify Buy RatingValuation and Risks. Our $32 price target is based on an equally weighted composite of: (a) $41/share, as a 25x multiple of taxed and diluted FY30 GAAP EPS of $2.78 discounted back to and (b) an NPV of $23/share (discount rate 12%, growth rate 2%).

Sean Laaman

Morgan Stanley

$24→$25

Hold

10.77%

Upside

Reiterated

11/06/25

ACADIA Pharmaceuticals: Hold Rating Amid Stable U.S. Performance and Growth Potential

Sumant Kulkarni

Canaccord Genuity

$32

Buy

41.78%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), InMode (NASDAQ: INMD) and Pennant Group (NASDAQ: PNTG)Nuplazid and Daybue motor along nicely as we await data in 2026 and beyond; reiterate BUY, $32 PT

Yigal Nochomovitz

Citi

$33

Buy

46.21%

Upside

Assigned

11/06/25

ACADIA Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating

Matthew Hershenhorn

Oppenheimer

$21

Hold

-6.96%

Downside

Reiterated

11/06/25

ACADIA Pharmaceuticals (ACAD) Gets a Hold from Oppenheimer

Ritu Baral

TD Cowen

$35

Buy

55.07%

Upside

Reiterated

11/05/25

ACADIA Pharmaceuticals: Strategic Expansion and Strong Market Presence Drive Buy RatingWe think this new commercial strategy will drive more NRx growth in 2026. With increased Nuplazid demand and a 3Q25 beat, ACAD is expanding its PDP salesforce by 30% in 1Q26 to accelerate growth. Ph2 ADP '204 data are due mid-2026.

Brian Abrahams

RBC Capital

$34→$32

Buy

41.78%

Upside

Reiterated

11/05/25

RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

Tazeen Ahmad

Bank of America Securities

$27

Hold

19.63%

Upside

Reiterated

11/05/25

ACADIA Pharmaceuticals: Hold Rating Amid Growth Prospects and Uncertainties

Uy Ear

Mizuho Securities

$22→$24

Hold

6.34%

Upside

Reiterated

10/08/25

Mizuho Securities Remains a Hold on ACADIA Pharmaceuticals (ACAD)We maintain our $24 PT and Neutral rating.

Marc Goodman

Leerink Partners

$32→$30

Buy

32.92%

Upside

Reiterated

10/07/25

Leerink Partners Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

Tessa Romero

J.P. Morgan

$34→$33

Buy

46.21%

Upside

Reiterated

09/29/25

J.P. Morgan Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)JPMorgan analyst Tessa Romero lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $34.00) while maintaining a Overweight rating.

Evan Seigerman

BMO Capital

$28→$26

Buy

15.20%

Upside

Reiterated

09/25/25

BMO Capital Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

David Hoang

Deutsche Bank

$35→$29

Buy

28.49%

Upside

Reiterated

09/25/25

Acadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche BankAcadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche Bank

Joel Beatty

Robert W. Baird

$31

Buy

37.35%

Upside

Reiterated

09/24/25

ACADIA Pharmaceuticals (ACAD) Receives a Buy from Robert W. BairdBaird analyst Joel Beatty reiterated an Outperform rating and $31.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

$28→$29

Buy

28.49%

Upside

Reiterated

11/06/25

Positive Indicators and Growth Prospects Lead to Buy Rating for ACADIA Pharmaceuticals

Ananda Ghosh

H.C. Wainwright

$32

Buy

41.78%

Upside

Reiterated

11/06/25

Sean Laaman

Morgan Stanley

$24→$25

Hold

10.77%

Upside

Reiterated

11/06/25

ACADIA Pharmaceuticals: Hold Rating Amid Stable U.S. Performance and Growth Potential

Sumant Kulkarni

Canaccord Genuity

$32

Buy

41.78%

Upside

Reiterated

11/06/25

Yigal Nochomovitz

Citi

$33

Buy

46.21%

Upside

Assigned

11/06/25

ACADIA Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating

Matthew Hershenhorn

Oppenheimer

$21

Hold

-6.96%

Downside

Reiterated

11/06/25

ACADIA Pharmaceuticals (ACAD) Gets a Hold from Oppenheimer

Ritu Baral

TD Cowen

$35

Buy

55.07%

Upside

Reiterated

11/05/25

Brian Abrahams

RBC Capital

$34→$32

Buy

41.78%

Upside

Reiterated

11/05/25

RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

Tazeen Ahmad

Bank of America Securities

$27

Hold

19.63%

Upside

Reiterated

11/05/25

ACADIA Pharmaceuticals: Hold Rating Amid Growth Prospects and Uncertainties

Uy Ear

Mizuho Securities

$22→$24

Hold

6.34%

Upside

Reiterated

10/08/25

Mizuho Securities Remains a Hold on ACADIA Pharmaceuticals (ACAD)We maintain our $24 PT and Neutral rating.

Marc Goodman

Leerink Partners

$32→$30

Buy

32.92%

Upside

Reiterated

10/07/25

Leerink Partners Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

Tessa Romero

J.P. Morgan

$34→$33

Buy

46.21%

Upside

Reiterated

09/29/25

Evan Seigerman

BMO Capital

$28→$26

Buy

15.20%

Upside

Reiterated

09/25/25

David Hoang

Deutsche Bank

$35→$29

Buy

28.49%

Upside

Reiterated

09/25/25

Acadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche BankAcadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche Bank

Joel Beatty

Robert W. Baird

$31

Buy

37.35%

Upside

Reiterated

09/24/25

ACADIA Pharmaceuticals (ACAD) Receives a Buy from Robert W. BairdBaird analyst Joel Beatty reiterated an Outperform rating and $31.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ACADIA Pharmaceuticals

1 Month

xxx

Success Rate

17/30 ratings generated profit

Average Return

+0.88%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.67% of your transactions generating a profit, with an average return of +0.88% per trade.

3 Months

xxx

Success Rate

7/13 ratings generated profit

Average Return

+1.83%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +1.83% per trade.

1 Year

Ami FadiaNeedham

Success Rate

8/13 ratings generated profit

Average Return

+10.83%

reiterated a buy rating 4 days ago

Copying Ami Fadia's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +10.83% per trade.

2 Years

xxx

Success Rate

10/13 ratings generated profit

Average Return

+20.42%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.92% of your transactions generating a profit, with an average return of +20.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACAD Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACAD has received 26 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. ACAD average Analyst price target in the past 3 months is 30.35.

Each month's total comprises the sum of three months' worth of ratings.

ACAD Financial Forecast

ACAD Earnings Forecast

Next quarter’s earnings estimate for ACAD is $0.14 with a range of $0.05 to $0.23. The previous quarter’s EPS was $0.42. ACAD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ACAD has Preformed in-line its overall industry.

ACAD Sales Forecast

Next quarter’s sales forecast for ACAD is $291.51M with a range of $281.64M to $300.00M. The previous quarter’s sales results were $278.63M. ACAD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ACAD has Preformed in-line its overall industry.

ACAD Stock Forecast FAQ

What is ACAD’s average 12-month price target, according to analysts?

Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is 30.35.

What is ACAD’s upside potential, based on the analysts’ average price target?

ACADIA Pharmaceuticals has 34.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACAD a Buy, Sell or Hold?

ACADIA Pharmaceuticals has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.

What is ACADIA Pharmaceuticals’s price target?

The average price target for ACADIA Pharmaceuticals is 30.35. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $39.00 ,the lowest forecast is $21.00. The average price target represents 34.47% Increase from the current price of $22.57.

What do analysts say about ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of ACAD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

ACAD Analyst Ratings

ACAD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ACADIA Pharmaceuticals

ACAD Analyst Recommendation Trends

ACAD Financial Forecast

ACAD Earnings Forecast

ACAD Sales Forecast

ACAD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts